Eli Lilly and Company (LLY)

189.25
+3.33(+1.79%)
Pre Market
188.79
-0.46(-0.24%)
- Real-time Data
  • Volume:
    3,732,096
  • Bid/Ask:
    188.23/189.80
  • Day's Range:
    186.88 - 190.30

LLY Overview

Prev. Close
189.25
Day's Range
186.88 - 190.3
Revenue
24.54B
Open
187.38
52 wk Range
129.21 - 218
EPS
6.79
Volume
3,732,096
Market Cap
181.49B
Dividend (Yield)
3.40 (1.83%)
Average Vol. (3m)
4,039,693
P/E Ratio
27.88
Beta
0.26
1-Year Change
20.32%
Shares Outstanding
958,992,159
Next Earnings Date
Apr 27, 2021
What is your sentiment on Eli Lilly and Company?
or
Market is currently closed. Voting is open during market hours.

Eli Lilly and Company News

Eli Lilly and Company Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyStrong BuyBuy
Technical IndicatorsSellStrong BuyStrong BuyBuyStrong Buy
SummaryNeutralStrong BuyStrong BuyStrong BuyStrong Buy

Eli Lilly and Company Company Profile

Eli Lilly and Company Company Profile

Employees
35000

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.

Read More
  • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
    0
    • 184 should be the bottom....
      0
      • 180?
        0
      • 10
        0
    • duddddddd
      0
      • Tomorrow up 5 percent minimum. stock up
        1
        • I think the people selling should consider getting in the trial for donanemab.
          0
          • what problem?
            0
            • Breakout coming . 220+ coming
              0
              • Just in: Lilly has reached another milestone in our fight against the pandemic. The @US_FDA has granted Emergency Use Authorization for another Lilly antibody therapy to treat mild to moderate #COVID19 in high-risk patients. Learn more: e.lilly/2Ndy3Ha
                0
                • Let’s go again 🚀🚀🚀 target 300
                  1
                  • sold at 218 bye bye
                    1
                    • mustard rayon 1-29 it briefly hit its record high of 218 them dropped sharply
                      0
                    • hilarious if you lie check the prices before please.
                      0
                    • question fo you see the previous page does it say 53 week range 117.06 to hello 218 hello biff are you there or did they fo a bad lobotomy
                      0
                  • should go up well see
                    0
                    • overall a terrible day
                      0
                      • predictions look real good
                        1
                        • will earnings be good
                          0
                          • Today the plans ???? Target !?
                            0
                            • I bought some of Lly, should I not have. I'm still learning.
                              0
                              • You did very good😊Goes up😊
                                0
                            • back to 150. The report was base on small percentage of people. Other pharmaceutical have about the same early record and end up failing.
                              4
                              • as usual
                                0
                              • so short it and lose all your money
                                0
                            • Today we’re announcing positive Phase 2 #clinicaltrial data for a potential treatment to fight #Alzheimers disease. Learn more: e.lilly/3i3NInL
                              0
                              • Huge bubble, S&P PE @39!! scarly , its just next to the 2008! BE COUTIONS!
                                3
                                • Mmmm scarly crouton bubbles.
                                  0
                              • Eli Lilly and Co. will buy Prevail Therapeutics Inc. in a cash deal for approximately $1.04 billion.
                                0
                                • Walking dead stock
                                  3
                                  • MP stock on the rise
                                    0
                                    • It is good to have FRIENDS in HIGH places. I Mean white house.
                                      0
                                      • Added 10 shares today, mayb a mistake?
                                        2
                                        • mistake
                                          0
                                        • def not
                                          0
                                      • Why is it not going dip?
                                        2
                                        • not it going dip why is
                                          0
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.